Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2019 (H.R. 3396) Re-Introduced in U.S. House of Representatives, June 2019 New co-sponsors: September 2020 This is a similar bill to the ones known in the 112th Congress (2011-2012) as HR 2239, in the 113th Congress (2013-2014) as HR 842, in the 114thCongress (2015-2016) as HR
Beginning in 2007, the International Foundation for Gastrointestinal Disorders (IFFGD) began conducting a multi-year comprehensive survey of people with IBS, their experiences and unmet needs. This survey attracted a large number of responses internationally and its insights have been important contributions to IBS research, medical care and support systems since then. Now in 2020, IFFGD
April is IBS Awareness Month in many countries. During this month every year, increased and very needed attention is given to IBS and the experiences of those of us who live with it. Join IBS Impact, other affected people, families, friends, IBS and functional GI professionals and organizations who are uniting in our own ways
The International Foundation for Gastrointestinal Disorders (IFFGD) has announced the dates for its annual Advocacy Day event which, this year, will be Virtual Advocacy Day on June 27, 2020. This the day each year when a delegation of IFFGD staff, GI researchers, GI disorder-affected people and families gather to advocate with members of the U.S.
IBS Impact is posting this opportunity on behalf of the journalist. If you are interested, please contact her directly at the email or phone number below. ProPublica is a reputable, bipartisan online investigative journalism website within the U.S. “Have you been prescribed Linzess? If so I’d like to talk to you! I’m a reporter with
Today is Veterans Day in the U.S. Thank you to all veterans and current service members for your service. Veterans who served in the Southwest Asia or Afghanistan region at any time since 1990 are disproportionately affected by functional GI and motility disorders like IBS compared to the general population, for which FGIMDs are already
This past week, the U.S Food and Drug Administration (FDA) approved the sale and distribution of a new medication for irritable bowel syndrome with constipation (IBS-C), tenapanor, to be known by the brand name Ibsrela. Tenapanor, a 50 mg. daily oral medication is approved for adults. It has not been approved for youth under the
The U.S Food and Drug Administration (FDA) has approved marketing of the IB-Stim device, for use in adolescents, ages 11-18, with functional gastrointestinal pain related to irritable bowel syndrome (IBS). IB-Stim, developed by Innovative Health Solutions in Indiana, is a small nerve stimulator device powered by a battery and intended to be worn behind the
The Journal of the Canadian Association of Gastroenterology has newly published guidelines for the management of irritable bowel syndrome (IBS) in adults in its April 2019 issue. Twelve named authors from the fields of gastroenterology, health psychology and primary care, represent six Canadian universities with one author currently unaffiliated. These are McMaster University, the University
U.S. FDA Approves Return of Tegaserod (Zelnorm) to U.S. Market for Some Women with IBS-C, April 2019
At the end of March 2019, the U.S Food and Drug Administration (FDA) approved the reintroduction of tegaserod (brand name Zelnorm), an oral medication for irritable bowel syndrome with constipation (IBS-C) to the U.S., only for women without risk factors for or history of cardiovascular conditions. Tegaserod, a selective serotonin type 4 receptor partial agonist